Clinical Oncology
Volume 16, Issue 8 , Pages 569-574 , December 2004

A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer

  • S.C. Short

      Affiliations

    • The Royal Marsden Hospital Thyroid Unit, London and Sutton, UK
    • Corresponding Author InformationAuthor for correspondence: Dr S. C. Short, Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex, UK. Tel: +44-1923-825433; Fax: +44-1923-835210.
    • ,
  • A. Suovuori

      Affiliations

    • The Royal Marsden Hospital Thyroid Unit, London and Sutton, UK
    • ,
  • G. Cook

      Affiliations

    • The Royal Marsden Hospital Thyroid Unit, London and Sutton, UK
    • ,
  • G. Vivian

      Affiliations

    • Department of Nuclear Medicine, Derriford Hospital, Plymouth, UK
    • ,
  • C. Harmer

      Affiliations

    • The Royal Marsden Hospital Thyroid Unit, London and Sutton, UK

Received 2 March 2004 ,Revised 9 June 2004 ,Accepted 10 June 2004.

References 

  1. Asakawa H, Kobayashi T, Komoike Y, et al. Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma. Anticancer Res. 1997;17:2757–2762
  2. Wan YJ. Retinoic acid and its receptors. Am J Surg. 1993;166:50–53
  3. Lee HY, Dohi DF, Kim YH, et al. All-trans retinoic acid converts E2F into a transcriptional suppressor and inhibits the growth of normal human bronchial epithelial cells through a retinoic acid receptor-dependent signaling pathway. J Clin Invest. 1998;101:1012–1019
  4. Barroga EF, Kadosawa T, Okumura M, Fujinaga T. Effects of vitamin D and retinoids on the differentiation and growth in vitro of canine osteosarcoma and its clonal cell lines. Res Vet Sci. 1999;66:231–236
  5. Thompson KL, Hwang MS, Ahn CH, et al. Induction of p21/WAF1 and apoptosis by an RXR-selective retinoid in human prostate cancer cells. Proc AACR. 1996;230
  6. Li XS, Rishi AK, Shao ZM, et al. Posttranscriptional regulation of p21WAF1/CIP1 expression in human breast carcinoma cells. Cancer Res. 1996;56:5055–5062
  7. Nakagawa S, Fujii T, Yokoyama G, Kazanietz MA, Yamana H, Shirouza K. Cell growth inhibition by all-trans retinoic acid in SKBR-3 breast cancer cells: involvement of protein kinase Calpha and extracellular signal-regulated kinase mitogen-activated protein kinase. Mol Carcinog. 2003;38:106–116
  8. Bollag W, Holdener EE. Retinoids in cancer prevention and therapy. Ann Oncol. 1992;3:513–526
  9. Gumireddy K, Sutton LN, Phillips PC, Reddy CD. All-trans-retinoic acid-induced apoptosis in human medulloblastoma: activation of caspase-3/poly(ADP–ribose) polymerase 1 pathway. Clin Cancer Res. 2003;9:4052–4059
  10. Xu XC, Liu X, Tahara E, Lippman SM, Lotan R. Expression and up-regulation of retinoic acid receptor-beta is associated with retinoid sensitivity and colony formation in esophageal cancer cell lines. Cancer Res. 1999;59:2477–2483
  11. Shin DM, Xu XC, Lippman , et al. Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. Clin Cancer Res. 1997;3:875–880
  12. Pendino F, Dudognon C, Delhommeau F, et al. Retinoic acid receptor alpha and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death. Oncogene. 2003;22:9142–9150
  13. Chomienne C, Ballerini P, Balitrand N, et al. All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure–function relationship. Blood. 1990;76:1710–1717
  14. Schmutzler C, Brtko J, Biehert K, Kohrle J. Effects of retinoids and role of retinoic acid receptors in human thyroid carcinomas and cell lines derived there from. Exp Clin Endocrinol Diabetes. 1996;104(suppl 4):16–19
  15. Bassi V, Vitale M, Feliciello A, De Riu S, Rossi G, Fenzi G. Retinoic acid induces intercellular adhesion molecule-1 hyperexpression in human thyroid carcinoma cell lines. J Clin Endocrinol Metab. 1995;80:1129–1135
  16. Schreck R, Schnieders F, Schmutzler C, Kohrle J. Retinoids stimulate type I iodothyronine 5′-deiodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab. 1994;79:791–798
  17. Van Herle AJ, Agatep ML, Padua DN, et al. Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82 W-1) in vitro. J Clin Endocrinol Metab. 1990;71:755–763
  18. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol. 1999;141:443–457
  19. Schmutzler C, Koehrle J. Innovative strategies for the treatment of thyroid cancer. Eur J Endocrinol. 2000;143:15–24
  20. Paez Pereda M, Missale C, Grubler Y, Arzt E, Schaaf L, Stalla GK. Nerve growth factor and retinoic acid inhibit proliferation and invasion in thyroid tumor cells. Mol Cell Endocrinol. 2000;167:99–106
  21. Frankel SR, Eardley A, Heller G, et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med. 1994;120:278–286
  22. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165–1173
  23. Advani SH, Nair R, Bapna A, et al. Acute promyelocytic leukemia: all-trans retinoic acid (ATRA) along with chemotherapy is superior to ATRA alone. Am J Hematol. 1999;60:87–93
  24. Kitareewan S, Pitha-Rowe I, Sekula D, et al. UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2002;99:3806–3811
  25. Freemantle SJ, Spinella MJ, Dmitrovsky E, et al. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene. 2003;22:7305–7315
  26. Ledger GA, Mullan BP, O'Connor MK, et al. A pilot study on the use of 13-cis retinoic acid as an adjunct to radio-iodine therapy of metastatic thyroid cancer. Proceedings of the 76th Annual Meeting of Endocrine Society. 1994;417
  27. Simon D, Korber C, Kraush M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging. 2002;29:775–782
  28. Grunwald F, Menzel C, Bender H, et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med. 1998;39:1903–1906
  29. Hammersley PA, Al-Saadi A, Chittenden S, Flux GD, McCready VR, Harmer CL. Value of protein-bound radioactive iodine measurements in the management of differentiated thyroid cancer treated with (131)I. Br J Radiol. 2001;74:429–433
  30. Grunwald F, Pakos E, Bender H, et al. Redifferentiation therapy with retinoic acid in follicular thyroid cancer. J Nucl Med. 1998;39:1555–1558
  31. Haydon RC, Zhou L, Feng T, et al. Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res. 2002;8:1288–1294
  32. Jaremtchuk AV, Aman EF, Ponce W, et al. Low activity of 13-cis-retinoic acid plus interferon alpha 2a in advanced renal cell carcinoma. Am J Clin Oncol. 2002;25:123–125
  33. Niles RM. The use of retinoids in the prevention and treatment of skin cancer. Expert Opin Pharmacother. 2002;3:299–303
  34. Lin RJ, Egan DA, Evans RM, et al. Molecular genetics of acute promyelocytic leukemia. Trends Genet. 1999;15:179–184
  35. Um SJ, Han HS, Kwon YJ, et al. Novel retinoic acid derivative ABPN has potent inhibitory activity on cell growth and apoptosis in cancer cells. Int J Cancer. 2003;107:1038–1046
  36. Eigelberger MS, Wong MG, Duh QY, et al. Phenylacetate enhances the antiproliferative effect of retinoic acid in follicular thyroid cancer. Surgery. 2001;130:931–935
  37. Schmutzler C, Kohrle K. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid. 2000;10:393–406

PII: S0936-6555(04)00245-6

doi: 10.1016/j.clon.2004.06.018

Clinical Oncology
Volume 16, Issue 8 , Pages 569-574 , December 2004

Article Tools

* Image Usage & Resolution